Epigenetic modulator for cancer immunotherapy
4SC, an innovative German biotech company, is developing 4SC-202, a novel HDAC class I/LSD1 inhibitor for combination with cancer immunotherapy.
Please sign in or register for FREE to view this content
Register to EpigenomicsNet – the epigenetics and epigenomics network
EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.